[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578990":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":50,"collaborators":19,"id":53,"slug":19,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":19,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Bernstein Clinical Research Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"open-label administration","all subjects receive open-label lanadelumab",[12],"Biological: Lanadelumab 300 mg",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Lanadelumab 300 mg","no other intervention",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Jonathan Bernstein, MD","5139314181","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Karen Berendts","CONTACT","513-354-1746","kberendts@bernsteincrc.com",{"name":22,"role":28,"phone":19,"phoneExt":19,"email":32},"bernstja@ucmail.uc.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Bernstein Clinical Research Center, LLC","RECRUITING","Cincinnati","Ohio","45236","United States",{"type":42,"coordinates":43},"Point",[44,45],-84.51439,39.12711,{"lat":45,"lon":44},[48,49],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Jonathan A. Bernstein, MD","PI\u002F Owner","100578990",false,"NCT06818474","Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","Inclusion Criteria:\n\n* A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and\u002For paraproteinemia (e.g. monoclonal gammopathy of unknown significance)\n* historical attack rate of \\>= on attack per month prior to starting tranexamic acid (TAA)\n\nExclusion Criteria:\n\n* History of anaphylaxis or hypersensitivity to biologics\n* History of major systemic disease not well controlled in opinion of the PI\n* Women who are pregnant or breast feeding\n* Concurrent participation in other clinical trials\n* HAE Type 1 or 2 and normal complement HAE","ALL","18 Years",{"count":61,"type":62},5,"ESTIMATED","INTERVENTIONAL",[65],"PHASE4","use of lanadelumab in patients with acquired angioedema",[68],"Angioedema","2025-02-24",{"date":71,"type":72},"2025-02-25","ACTUAL",{"date":74,"type":72},"2024-06-01",{"date":76,"type":62},"2027-12-01",{"name":5,"class":6},1]